NCT04051268 - Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) | Biotech Hunter

Enrollment

3,071

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

November 24, 2021

Study Completion Date

December 1, 2021

Conditions

Safety IssuesImmunogenicity

Interventions

BIOLOGICAL

Vi-DT Typhoid Conjugate Vaccine

1 dose of Investigational Product

BIOLOGICAL

PQed Typhoid Conjugate Vaccine

1 dose of Active Comparator

BIOLOGICAL

Vi Polysaccharide Vaccine

1 dose of Active Comparator

Trial Locations (1)

Jatinegara Primary Health Care, Jakarta